Welcome to VanEck
Select Investor Type
Marketing Communication
CURE
Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF
Marketing Communication
CURE
Genomics ETF
VanEck Genomics and Healthcare Innovators UCITS ETF
ISIN:
IE000B9PQW54
Fund Description
Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.
-
NAV$21.59
as of 27 Feb 2026 -
YTD RETURNS-3.13%
as of 27 Feb 2026 -
Total Net Assets$14.5 million
as of 27 Feb 2026 -
Total Expense Ratio0.35%
-
Inception Date02 Sep 2022
-
SFDR ClassificationArticle 9
Overview
Fund Description
Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.The Fund has a sustainable investment objective, with an emphasis on social objectives:
- Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
- Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
- Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
- Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco
Main Risk Factors: Equity market risk, industry concentration risk, Liquidity Risks. Investors must consider all the fund's characteristics or objectives as detailed in the prospectus or related documents before making an investment decision. Please refer to the sustainability-related disclosures in the document section, to the
and the Prospectus for other important information before investing.
Underlying Index
MVIS® Global Future Healthcare ESG Index (MVFHCTR)
Fund Highlights
- Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
- Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
- Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
- Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco
Risk Factors: Equity market risk, industry concentration risk, Liquidity Risks. Investors must consider all the fund's characteristics or objectives as detailed in the prospectus or related documents before making an investment decision. Please refer to the sustainability-related disclosures in the document section, to the
and the Prospectus for other important information before investing.
Underlying Index
MVIS® Global Future Healthcare ESG Index (MVFHCTR)
Capital Markets
VanEck partners with esteemed market makers to ensure the availability of our products for trading on the mentioned stock exchanges. Our Capital Markets team is committed to continuously monitoring and assessing spreads, sizes, and prices to ensure optimal trading conditions for our clients. Furthermore, VanEck ETFs are available on various trading platforms, and we collaborate with a wider range of reputable Authorized Participants (APs) to promote an efficient and fair trading environment. For more information about our APs and to contact our Capital Markets team, please visit factsheet capital markets.pdfPerformance
Holdings
Portfolio
Documents
Index
Index Description
The MVIS Global Future Healthcare ESG Index is a global index that tracks the performance of companies that are involved in the genomic health care and electronic healthcare industries.
Index Key Points
Underlying Index
MVIS® Global Future Healthcare ESG Index (MVFHCTR)
The Index Composition:
The MVIS Global Future Healthcare ESG Index (MVFHCTR) tracks the performance of the largest and most liquid companies that are involved in the genomic health care and electronic healthcare industries. MVFHCTR covers at least 90% of the investable universe and adheres to ESG criteria.
Companies initially eligible for inclusion in Index:
- Companies involved in genomic health care or electronic healthcare industries. This includes companies with at least 50% (25% forcurrent components) of their revenues from the following sub-themes:
- Healthcare therapies based on the targeting or modification of genetic makeup of cells or uses mRNA
- Technology platforms that enable the development of genetics-based healthcare therapies
- Laboratory equipment or services used to test, code, or develop genetics-based healthcare therapies
- Software used to facilitate online medical consultations
- E-Commerce pharmacies
- Software for the management of medical practices and/or patient records
- Outpatient medical IoT devices
- Market capitalization greater than $150 million
- Three-month average daily turnover greater than $1 million
- Minimum trading volume of 250,000 shares each month over last 6 months
- Company weightings are capped at 8%.
Awards
Main Risks
Main Risk Factors of a Genomics ETF
The Fund’s assets may be concentrated in one or more particular sectors or industries. The Fund may be subject to the risk that economic, political or other conditions that have a negative effect on the relevant sectors or industries will negatively impact the Fund's performance to a greater extent than if the Fund’s assets were invested in a wider variety of sectors or industries.
The prices of the securities in the Fund are subject to the risks associated with investing in the securities market, including general economic conditions and sudden and unpredictable drops in value. An investment in the Fund may lose money.
Exists when a particular financial instrument is difficult to purchase or sell. If the relevant market is illiquid, it may not be possible to initiate a transaction or liquidate a position at an advantageous or reasonable price, or at all.